New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export SNY’s income statement to Excel — free account
Sanofi
SNYHealthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
46.62
0.56
+1.22%
Follow SNY
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 38,408 | 40,921 | 42,135 | 42,147 | 42,687 | 46,348 | 47,822 | 50,266 | 47,922 | 52,854 | 59,095 | +3.6% | — | — | — | — | |
| Gross margin, % | 69.17 | 67.93 | 67.95 | 68.18 | 67.47 | 68.72 | 69.83 | 69.35 | 70.18 | 72.07 | 73.44 | +2.9 pt | ||||||
| EBT | 6,283 | 6,251 | 5,202 | 3,161 | 15,768 | 9,226 | 10,981 | 7,742 | 7,248 | 6,986 | 7,151 | +1.2% | ||||||
| EBT margin, % | 16.36 | 15.27 | 12.35 | 7.50 | 36.94 | 19.91 | 22.96 | 15.40 | 15.12 | 13.22 | 12.10 | (3.1) pt | ||||||
| Net income | 5,211 | 9,533 | 5,085 | 3,143 | 14,066 | 7,362 | 8,820 | 5,844 | 5,947 | 5,588 | 4,506 | +0.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 14.93 | 16.28 | 16.89 | 16.86 | 17.03 | 18.50 | 19.10 | 20.08 | 19.15 | 21.65 | 24.62 | +4.2% | |||||
| Earnings | 2.03 | 1.76 | 2.04 | 1.24 | 5.61 | 2.94 | 3.52 | 2.33 | 2.48 | 3.62 | 2.02 | +6.6% | ||||||
| Cash flow | 3.37 | 3.32 | 2.63 | 3.47 | 3.39 | 4.97 | 4.43 | 4.43 | 3.93 | 4.98 | 9.91 | +4.4% | ||||||
| Capex | (0.81) | (0.64) | 0.09 | (0.27) | (0.54) | (0.63) | (0.30) | (0.87) | (0.75) | (1.25) | 0.00 | +5.0% | ||||||
| Free cash flow | 2.56 | 2.68 | 2.71 | 3.20 | 2.85 | 4.34 | 4.13 | 3.57 | 3.18 | 3.74 | 9.91 | +4.3% | ||||||
| Book value | 24.82 | 26.20 | 27.95 | 26.48 | 28.77 | 32.60 | 31.62 | 32.15 | 33.66 | 33.24 | 35.13 | +3.3% | ||||||
| Shares, m | 2,573 | 2,514 | 2,494 | 2,500 | 2,507 | 2,505 | 2,504 | 2,503 | 2,503 | 2,441 | 2,411 | (0.6%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 20.11 | 24.17 | 12.01 | 12.95 | 3.74 | 6.59 | 13.80 | 21.19 | 20.08 | 13.46 | 22.80 | 14.8 | |||||
| P/S | 2.75 | 2.66 | 2.06 | 2.04 | 1.91 | 1.87 | 2.57 | 2.49 | 2.52 | 2.24 | 1.87 | 2.3 | ||||||
| P/B | 1.65 | 1.65 | 1.61 | 1.90 | 1.58 | 1.62 | 1.55 | 1.56 | 1.43 | 1.46 | 1.37 | 1.6 | ||||||
| EV/Sales | 2.99 | 2.81 | 2.44 | 2.33 | 2.10 | 2.08 | 2.70 | 2.66 | 2.71 | 2.47 | 2.10 | 2.5 | ||||||
| EV/FCF | 8.24 | 6.69 | 6.84 | 8.39 | 8.80 | 7.52 | 5.01 | 5.16 | 6.33 | 7.02 | 7.43 | 7.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 8,674 | 8,340 | 6,551 | 8,673 | 8,509 | 12,449 | 11,090 | 11,102 | 9,827 | 12,163 | 23,793 | +3.8% | |||||
| Capex | (2,074) | (1,606) | 220 | (663) | (1,366) | (1,568) | (751) | (2,174) | (1,876) | (3,045) | (7,054) | +4.4% | ||||||
| Free cash flow | 6,600 | 6,734 | 6,771 | 8,010 | 7,143 | 10,881 | 10,339 | 8,928 | 7,950 | 9,118 | 23,793 | +3.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 11,346 | 12,315 | 8,507 | 9,218 | 16,512 | 10,966 | 10,601 | 7,009 | 14,528 | 2,950 | 3,959 | (13.9%) | |||||
| Net debt | 9,191 | 5,975 | 20,921 | 17,089 | 9,820 | 12,077 | 6,632 | 8,314 | 9,262 | 12,370 | 13,784 | +3.4% | ||||||
| Shareholders’ equity | 63,877 | 65,849 | 69,720 | 66,201 | 72,133 | 81,671 | 79,180 | 80,472 | 84,249 | 81,133 | 84,300 | +2.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 4.54 | 8.34 | 4.16 | 2.44 | 10.94 | 5.39 | 6.40 | 4.32 | 4.29 | 6.16 | 3.24 | +1.6 pt | |||||
| ROIC | 6.49 | 6.15 | 4.30 | 5.46 | 12.50 | 6.56 | 7.81 | 6.75 | 5.49 | 6.57 | 7.05 | +0.1 pt | ||||||
| ROE | 8.11 | 14.70 | 7.50 | 4.62 | 20.34 | 9.57 | 10.97 | 7.32 | 7.31 | 10.69 | 0.00 | +2.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 106,859 | 106,566 | 104,226 | 100,409 | 99,412 | 95,442 | 91,573 | 86,088 | 82,878 | 74,846 | — | (3.9%) | |||||
| Revenue/emp, $m | 0.36 | 0.38 | 0.40 | 0.42 | 0.43 | 0.49 | 0.52 | 0.58 | 0.58 | 0.71 | — | +7.8% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 5, 2026
Sanofi vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NVS Novartis AG | $277.7B | 28.8× | 24.0× FY26e | +4.67% (above 0%: growing) | −68.81% (below 0%: shrinking) | −17.81% (below 0%: shrinking) | 75.99% | 12.26% | Compare |
| AZN AstraZeneca PLC | $272.1B | 24.6× | 24.2× FY26e | +6.70% (above 0%: growing) | +23.46% (above 0%: growing) | +1.99% (above 0%: growing) | 81.82% | 27.07% | Compare |
| AMGN Amgen Inc. | $237.4B | 25.2× | 24.0× FY26e | +8.45% (above 0%: growing) | +19.39% (above 0%: growing) | −13.98% (below 0%: shrinking) | 73.10% | 35.79% | Compare |
| GILD Gilead Sciences, Inc. | $207.8B | — (loss-making) | — (loss-making) | +6.83% (above 0%: growing) | −20.16% (below 0%: shrinking) | +21.13% (above 0%: growing) | 81.07% | 41.71% | Compare |
| PFE Pfizer Inc. | $158.2B | 38.8× | 18.7× FY26e | −0.43% (below 0%: shrinking) | −9.68% (below 0%: shrinking) | +20.02% (above 0%: growing) | 75.71% | 22.14% | Compare |
| NVO Novo Nordisk A/S | $128.6B | 9.8× | — | +3.87% (above 0%: growing) | −17.14% (below 0%: shrinking) | −14.75% (below 0%: shrinking) | 76.97% | 29.06% | Compare |
| BMY Bristol Myers Squibb Company | $119.3B | 12.9× | 12.0× FY26e | +6.93% (above 0%: growing) | −2.78% (below 0%: shrinking) | −35.95% (below 0%: shrinking) | 68.28% | 19.40% | Compare |
| SNY Sanofi | $111.3B | 22.8× | — | +13.89% (above 0%: growing) | +8.21% (above 0%: growing) | +99.60% (above 0%: growing) | 76.16% | 28.53% | |
| GSK GSK PLC Sponsored ADR | $95.9B | 16.4× | 15.5× FY26e | +3.75% (above 0%: growing) | −23.88% (below 0%: shrinking) | +62.44% (above 0%: growing) | 73.11% | 23.93% | Compare |
| Median of peers | $183.0B | 24.6× | 21.4× | +5.69% | −13.41% | −5.99% | 75.85% | 25.50% |
Sanofi (SNY) Latest News
What happened
- Deal Sanofi reportedly considered acquiring Insmed, a drugmaker valued at about $26.6 billion, but discussions were preliminary and no deal was assured.
- Product The FDA approved Sanofi's Infilbray for neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15 kg.
- Product The European Commission approved Sanofi's VaxRabeo for rabies prevention before and after exposure across all ages.
- Deal Sanofi signed a multi-target research and exclusive licensing deal with Seawolf worth up to $1.2 billion in milestone payments, plus tiered royalties.
- Sanofi (SNY) Q3 2026 Earnings Call Transcript The Motley Fool transcript
- Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance Investing.com
- Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded GlobeNewswire
- Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? Zacks
- Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe PR Newswire
- Sanofi expands Canadians' COVID-19 vaccine choice with availability of Nuvaxovid®for the 2026-2027 respiratory season CNW Group
- Regeneron’s Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings 24/7 Wall St.
- Novartis Reports Lower Relapse Rates and No Hy’s Law Cases in Phase 3 Remibrutinib MS Trials InvestorsHub
- Novartis MS drug remibrutinib cuts relapses, no liver safety signal in trials Investing.com
- Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial clinicaltrialsarena.com
9 more headlines
- Sanofi (SNY) Is Planning for a Patent Loss, Here’s Where Bulls Still See Opportunity Insider Monkey
- Sanofi Stock And Why Earnings Guidance Raised Matters For Shareholders Simply Wall St.
- Sanofi (ENXTPA:SAN) Stock Can Q3 Earnings Sustain Its Revenue Strength Simply Wall St.
- Sanofi Q3 Earnings Call Highlights MarketBeat
- Regeneron Soars 12% on Dupixent-Fueled Q3 Beat: “One of Our Strongest Years Ever” TIKR
- Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise Zacks
- Regeneron Reports Third Quarter 2026 Financial and Operating Results GlobeNewswire
- Parse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune Biology Business Wire
- Sanofi and ScionxBio partner on mRNA therapies pharmaceutical-technology.com
SNY metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score